Weekly roundup: Sanofi seals a US$1.6bn deal with Vicebio and collaborates with Kling
Sanofi to acquire next-generation vaccine biotech Vicebio for US$1.6 billion
Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has entered an exclusive, definitive agreement to be acquired by Sanofi. Under the terms of the agreement, and subject to customary conditions, Vicebio shareholders will receive up to a total of US$1.6 billion, including an upfront payment of US$1.15 billion, as well as development and regulatory milestones payments of US$450 million.
Congratulations to the Vicebio team!
Kling Bio announces collaboration with Sanofi for accelerated discovery of neutralising antibodies
Kling Bio, a biotech company developing antibody-based drugs for cancer and infectious diseases, announced that it has entered into a collaboration and license option agreement with Sanofi for the discovery of antibodies and epitopes using Kling-Select, its groundbreaking B cell immortalisation and screening platform.
Neuraxpharm continues international expansion with the launch of Neuraxpharm Australia
Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launch of a new affiliate, Neuraxpharm Australia, led by newly appointed Head of Commercial, Avendran Naidu, as the Company continues to expand globally.
Neuraxpharm also announced that leriglitazone’s MAA has been validated by EMA
Minoryx Therapeutics and Neuraxpharm announced that the Marketing Authorization Application (MAA) for Minoryx’s lead candidate leriglitazone (NEZGLYAL®) has been submitted to the European Medicines Agency (EMA) for the treatment of paediatric and adult male patients with cerebral adrenoleukodystrophy (cALD). EMA has now validated the MAA file, and it is under review by the Committee for Medicinal Products for Human Use.
📺Optimum TV
In the latest episode of Optimum TV’s Dealmakers, Felice Verduyn – van Weegen, Partner at EQT Life Sciences, talks about what sets the firm apart. “EQT was looking to get closer to the front lines of innovation,” says Felice. Watch the full episode here ⬇️
🔥Hot topic
The British government recently announced that it is to use AI to scan hospital data to help spot medical scandals early. Stephen Adams asks why it typically takes years – and sometimes decades – for such scandals to emerge, and whether the adoption of AI technology will be enough to prevent them. Learn more in the latest hot topic.
👥Industry events
Optimum’s 17th Annual Healthcare Conference
Returning to The King’s Fund this autumn, this prestigious invitation-only event brings together investors and executives from across the life sciences sector, register your interest in attending today.
📍Thursday 9th October, London
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
